Research Program

STAGED APPROACH FROM LAB TO CLINIC

 

BioCanRx provides funding to translate promising biotherapeutic discoveries from the lab to the clinic, with a particular emphasis on Clinical Trials / Investigational New Drug (IND) enabling work to support clinical trial applications. Our core research program involves a staged approach driven by milestones. Through three distinct cancer research programs and levels of funding in our development pipeline, projects flow progressively towards the clinic.
 
BioCanRx bolsters these three programs through access to specialized core facilities in the network (such as infrastructure to produce biotherapeutics for use in human clinical trials) and through our Clinical, Social and Economic Impact (CSEI) research program that evaluates and positions the technologies intake into the health care system.

 

We invest in projects that will:

 

  • lead to unique clinical trials that support our mission
  • develop tools and processes that are valuable to our network members and will foster an emerging sector for cancer biotherapeutics in Canada

 

OUR RESEARCH INVESTMENT PROGRAM
BioCanRx Annual Report 2015-16

 

MORE ABOUT OUR RESEARCH PROGRAMS

 

CLINICAL TRIALS PROGRAM
The Clinical Trials Program provides funds for Phase I clinical trials of novel cancer biotherapies that have been substantially developed in Canada.

Approximately $4 million is available from BioCanRx over five years.

  • BioCanRx will contribute to a maximum of 40% for the costs of a clinical trial.
  • The trial must have Canadian content in its approach (not a “me too” trial or a big pharma trial in disguise).
  • The project must be collaborative, such as:
    • include multiple sites so the therapeutic is more widely available across Canada
    • use core facilities in other network institutions

Our Research Management Committee is looking for:

  • outstanding science in an international context
  • Canadian innovation that is an integral element of the trial’s approach
  • evidence that partnerships and funding will follow investment by BioCanRx
  • therapies with a reasonable expectation that the health-care system will pay for them if a trial succeeds at Phase III
  • a budget and project plan that makes sense

 
Browse our Funded Clinical Trials.

 
ENABLING STUDIES PROGRAM

The Enabling Studies Program funds work required to prepare and position biotherapeutic products and platforms for clinical testing in patients. It bridges the traditionally difficult-to-fund translation from the laboratory to clinical testing. Data collected in these projects will enable completion of a clinical trials application.

Approximately $5.5 million is available from BioCanRx over five years.

  • BioCanRx will contribute to a maximum of 50% for the costs of Enabling Studies.
  • These projects could support GMP (good manufacturing process) and GLP (good laboratory process) studies, dosing and toxicology studies, process development, assay development and preparation for a clinical trial application (CTA).
  • Enabling Studies must be collaborative (across sectors or institutions).
  • They must result in one or both of these deliverables:

Our Research Management Committee is looking for:

  • a project whose outcome is a trial that we would fund through the Clinical Trials Program
  • critical experiments that will lead to a clinical trial application and bolster its chances of approval by Health Canada
  • a budget and project plan that makes sense

 
Browse our Funded Enabling Studies.

 
CATALYST PROGRAM

The Catalyst Program supports short-term, early stage projects that can advance to the next stage in the BioCanRx research pipeline, or generate scientific tools and methods that can be used by other BioCanRx network researchers.

Approximately $3.5 million is available from BioCanRx over five years.

  • BioCanRx will contribute to a maximum of 50% for the costs of a Catalyst Program project.
  • These projects are from six to 24 months in length.
  • Catalyst Program projects are technology or product oriented; not fundamental science
  • They must be collaborative (across sectors or institutions)

Our Research Management Committee is looking for:

  • a project with clear and direct relevance to cancer biotherapeutics; not a contrived story
  • Catalyst Program projects could include:
    • validation of manufacturing process improvements or companion technologies that may enhance manufacturing or testing of BioCanRX products
    • validation of technologies that may apply to clinical evaluation of BioCanRX products (e.g., imaging, biomarker validation, immunological monitoring)
    • proof-of-concept preclinical studies validating the efficacy of combining biotherapeutics
  • a budget and project plan that makes sense

 
Browse our Funded Catalyst Projects.

 
CLINICAL, SOCIAL AND ECONOMIC IMPACT (CSEI) PROGRAM

The objective of the CSEI Program is to develop potential solutions to social, legal, ethical, economic or health-systems barriers facing BioCanRx biotherapeutic products and platforms as they progress through the translational pipeline from preclinical research to clinical trials.

Approximately $1.5 million is available from BioCanRx over five years.

  • BioCanRx will contribute to a maximum of 50% for the costs of a CSEI Program project.
  • CSEI Program projects must be collaborative (across sectors or institutions)

Our Research Management Committee is looking for:

  • relevance to the BioCanRx mandate
  • relevance to barriers in the translation of BioCanRx technologies into clinical testing and/or uptake by relevant receptors
  • scientific excellence, creativity and innovation, in an international context
  • feasibility of the study and of the access to required resources and expertise
  • a team and project that is multidisciplinary and collaborative
  • a commitment and level of involvement from partners, or potential for new partners to engage
  • a budget and project plan that makes sense
 
CORE FACILITIES PROGRAM

This program is intended to provide a baseline level of support for core facilities engaged in BioCanRx projects, which are not already receiving facility staff or maintenance support within the budgets of those BioCanRx projects. Support from this program is intended to principally fund one HQP within a GMP or GLP laboratory/core facility, but may also include support for minor expenses related to ongoing facility maintenance, certification or baseline operation.

The range of allowable support is $75,000 to $100,000 per facility annually.

Our Research Management Committee is looking for:

  • relevance to the BioCanRx mandate (i.e., accelerating translation of novel innovations in cancer biotherapeutics)
  • extent of involvement in BioCanRx sponsored projects
  • appropriate budget justification; and
  • track record of the applicants/core facility.

 
We’re not currently accepting applications for core facilities.